VICENTE
ESTRADA PÉREZ
Profesor asociado de Ciencias de la Salud
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (22)
2023
-
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 11, pp. 2696-2701
2022
-
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
Open Forum Infectious Diseases
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
2021
-
Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV
PloS one, Vol. 16, Núm. 4, pp. e0249515
-
Standardized comparison of cardiovascular risk factors prevalence in spanish women and men living with hiv and in the general population
Journal of Personalized Medicine, Vol. 11, Núm. 11
-
eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort
HIV Research and Clinical Practice, Vol. 22, Núm. 3, pp. 78-85
2019
-
Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 39, Núm. 5, pp. 497-505
-
Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 6, pp. 373-379
2017
-
Very low level viraemia and risk of virological failure in treated HIV-1-infected patients
HIV Medicine, Vol. 18, Núm. 3, pp. 196-203
2016
-
Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics
Open Forum Infectious Diseases, Vol. 3, Núm. 2
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
2015
-
Cardiovascular risk factors and lifetime risk estimation in hiv-infected patients under antiretroviral treatment in Spain
HIV Clinical Trials, Vol. 16, Núm. 2, pp. 57-65
-
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792
2014
-
Documento de consenso: Recomendaciones para el manejo de la enfermedad ósea metabólica en pacientes con virus de la inmunodeficiencia humana
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 4, pp. 250-258
-
Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A clinical and molecular study
PLoS ONE, Vol. 9, Núm. 2
2012
-
Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy
AIDS Reviews, Vol. 14, Núm. 2, pp. 112-123
-
Switching to raltegravir in virologically suppressed in HIV-1-infected patients: A retrospective, multicenter, descriptive study
Current HIV Research, Vol. 10, Núm. 8, pp. 673-678
2011
2009
-
Disorders of body fat distribution in HIV-1-infected patients
AIDS Reviews, Vol. 11, Núm. 3, pp. 126-134